Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy.
Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy.
Liver Int. 2021 Jun;41(6):1290-1293. doi: 10.1111/liv.14828. Epub 2021 Mar 3.
Data are limited on the epidemiological implications of the recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD). We therefore performed a cross-sectional study of adults recruited in the 2017-2018 National Health and Nutrition Examination Survey, a representative sample of the general US population. The prevalence of NAFLD and MAFLD based on controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) obtained through vibration-controlled transient elastography (VCTE) were 37.1% (95% CI 34.0-40.4) and 39.1% (95% CI 36.3-42.1), respectively, with higher rates among Hispanic individuals. Agreement between the two definitions was high (Cohen's κ 0.92). Patients with NAFLD and MAFLD also showed similar risk of advanced liver fibrosis (7.5% and 7.4% respectively). Our results suggest that the recent change in diagnostic criteria did not affect the prevalence of the condition in the general United States population.
关于术语最近从非酒精性脂肪性肝病（NAFLD）改为代谢相关脂肪性肝病（MAFLD）的流行病学意义的数据有限。因此，我们对 2017-2018 年全国健康和营养调查中招募的成年人进行了横断面研究，这是美国一般人群的代表性样本。基于受控衰减参数（CAP）和通过振动控制瞬态弹性成像（VCTE）获得的肝硬度测量（LSM）的 NAFLD 和 MAFLD 的患病率分别为 37.1%（95%CI 34.0-40.4）和 39.1%（95%CI 36.3-42.1），西班牙裔个体的患病率更高。两种定义之间的一致性很高（Cohen's κ 0.92）。NAFLD 和 MAFLD 患者的晚期肝纤维化风险也相似（分别为 7.5%和 7.4%）。我们的研究结果表明，最近诊断标准的改变并未影响美国一般人群中该疾病的患病率。
J Clin Endocrinol Metab. 2021-7-13
J Gastroenterol Hepatol. 2021-6
Front Endocrinol (Lausanne). 2021
Clin Exp Med. 2025-6-18
Zotero 插件